ARIAD Pharmaceuticals Inc
featured
A group of doctors likens the high prices for a life-saving medicine as profiteering, akin to jacking up prices of essential goods after a natural disaster. The NYT reports.
» Read More
More
-
Cramer makes the call on viewers' favorite stocks.
-
The "Mad Money" host sits down with Harvey Berger to talk prospects and products in the pipeline.
-
Mad Money host Jim Cramer and Harvey Berger, Ariad Pharmaceuticals chairman/CEO, discuss the state of the health care sector and Ariad's recent research for Sarcoma, Leukemia and other cancers.
-
Stocks ended narrowly mixed in a lackluster session Wednesday following a weaker-than-expected existing home sales report and as investors were reluctant to jump in following the recent market rally.
-
U.S. stock index futures hovered around the flatline Wednesday after a pullback in the previous session amid economic outlook worries over China.
-
Savvy investors know that making money on the “ASCO trade” means getting in early as cancer drug stocks typically trade up into the closely watched medical meeting.
-
Harvey Berger, Ariad Pharmaceuticals chairman & CEO, discusses pending FDA approval of its two commercial cancer drugs and what is driving the boom in the stock.
-
Cramer makes the call on viewers' favorite stocks.
-
See what's happening, who's talking and what will be making headlines on Monday's Squawk on the Street.
-
The Lightning Round is extended in this CNBC.com exclusive feature.
-
The Lightning Round is extended in this CNBC.com exclusive feature.
-
Techs or pharmeceuticals — which is the better buy for investors? Uri Landesman, president of Platinum Partners and Philip Tasho, CEO and CIO at Tamro Capital shared their insights.
-
Stocks trading under $5 typically have no analysts' coverage. However, a select few boast of favorable coverage from analysts. The following 10 U.S. stocks trade at less than $5 and have garnered the most "buy" ratings from analysts. ...A report from TheStreet.
-
This is gonna be a crazy couple of days. At 9 pm ET tonight the American Society of Clinical Oncology is putting nearly 5,000 studies on its website all at once. Although ASCO says it's all about the science and protecting the "scientific integrity" of its upcoming conference, this is, frankly, an attempt to level the playing field for Wall Street.
-
Occasionally -- when the bosses will let me -- I take a day to network, learn and maybe pick up a story idea by attending a biotech or healthcare investment conference. Many firms put on the events for their clients and they often invite reporters to hang out. ... The PR guy told me a couple of sessions during the day would be "closed" to me. It wasn't clear what the closed sessions were all about, and so my curiousity was piqued...
-
Ariad Pharmaceuticals said a U.S. federal court ruled in favor of it and co-complainants in a patent infringement case against Eli Lilly, saying that the patent was valid and enforceable.
